Cara Therapeutics reported $158.78M in Equity Capital and Reserves for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Acadia Pharmaceuticals ACAD:US USD 400.41M 25.27M
Acelrx Pharmaceuticals ACRX:US USD 27.54M 5.6M
Cara Therapeutics CARA:US USD 158.78M 26.04M
Chugai Pharma 4519:JP JPY 1.42T 115.76B
Depomed DEPO:US USD 225.72M 90.81M
Endo International Ordinary Shares ENDP:US USD -3925041000 726.97M
Halozyme Therapeutics HALO:US USD 169.8M 72.81M
Horizon Pharma HZNP:US USD 5.07B 38.49M
Neurocrine Biosciences NBIX:US USD 1.71B 163.2M
Pacira Pharmaceuticals PCRX:US USD 775.01M 4.89M
Pain Therapeutics PTIE:US USD 227.54M 28.82M
Revance Therapeutics RVNC:US USD 12.6M 133.11M
Supernus Pharmaceuticals SUPN:US USD 886.2M 33.41M
Teva Pharmaceutical Industries TEVA:US USD 7.9B 871M
Vanda Pharmaceuticals VNDA:US USD 527.2M 11.54M